Clinical Trial

VergeRx for Smokers Not Ready to Quit

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study uses a factorial optimization experiment to identify which treatment components help adults who smoke and are not ready to quit in the next 30 days (smokers not ready to quit, or SNRTQ) achieve smoking cessation. Participants are recruited through Federally Qualified Health Centers (FQHCs) in Virginia and West Virginia. All participants receive at least 8 weeks of nicotine replacement therapy (NRT) patch. Using a 2×2×2×2 factorial design, the study independently tests four components: a pharmacist-delivered behavioral program (VergeRx), a text-message support program (SmokefreeTXT), the addition of an NRT lozenge to the patch, and an extended 16-week course of the NRT patch versus the standard 8 weeks. The goal is to estimate the effect of each component on biochemically confirmed smoking abstinence so that an optimized treatment package can be assembled. The primary outcome is abstinence at 26 weeks; a secondary outcome is abstinence at 52 weeks.
Trial Details
NCT Number NCT07693660
Lead Sponsor University of Virginia
Collaborators: National Cancer Institute (NCI)
Conditions Tobacco Use Cessation
Enrollment 592 participants
Start Date 2027-12-01
Primary Completion 2031-12-01 (estimated)
Study Completion 2032-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09